TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Open-label, Multicenter Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab) and CAL-101 (Idelalisib) Followed by CAL-101 and GA101 Maintenance in CLL Patients
Brief Summary: The CLL2-BCG-trial is a prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of a debulking with bendamustine followed by an induction with GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101-maintenance in CLL patients


Options:
A: Arm Label: Idelalisib+ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Idelalisib, Drug: Ofatumumab | Arm Label: Ofatumumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib+ofatumumab | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Idelalisib+ofatumumab, Ofatumumab
B: Arm Label: Bendamustine + GA101 + CAL-101; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: CAL-101 | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: CAL-101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101
C: Arm Label: ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): ibrutinib
D: Arm Label: Arm A - Obinutuzumab in Combination with Chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Arm Label: Arm B - Acalabrutinib in Combination with Obinutuzumab; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib, Drug: Obinutuzumab | Arm Label: Arm C - Acalabrutinib Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib | Intervention Type: DRUG; Name: Acalabrutinib; Assigned to Arm(s): Arm B - Acalabrutinib in Combination with Obinutuzumab, Arm C - Acalabrutinib Monotherapy | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil, Arm B - Acalabrutinib in Combination with Obinutuzumab | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of the study is to compare efficacy and safety of palliative chemotherapy EOX and mDCF regimens in the first-line treatment of patients with advanced HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma


Options:
A: Arm Label: Cohort A: Triple Negative Breast Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B: Head & Neck Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort C: Urothelial Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort D: Gastric Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B2: Head & Neck Cancer Expansion; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Cohort A: Triple Negative Breast Cancer, Cohort B2: Head & Neck Cancer Expansion, Cohort B: Head & Neck Cancer, Cohort C: Urothelial Cancer, Cohort D: Gastric Cancer
B: Arm Label: Trastuzumab, Fluoropyrimidine, Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Fluoropyrimidine, Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Fluorouracil; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin
C: Arm Label: EOX; Type: ACTIVE_COMPARATOR; Interventions: Other: EOX | Arm Label: mDCF; Type: ACTIVE_COMPARATOR; Interventions: Other: mDCF | Intervention Type: OTHER; Name: EOX; Assigned to Arm(s): EOX | Intervention Type: OTHER; Name: mDCF; Assigned to Arm(s): mDCF
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: TS-1 and cisplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: TS-1 | Intervention Type: DRUG; Name: TS-1 and cisplatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: TS-1; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of the study is to compare efficacy and safety of palliative chemotherapy EOX and mDCF regimens in the first-line treatment of patients with advanced HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma


Options:
A: Arm Label: Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)
C: Arm Label: EOX; Type: ACTIVE_COMPARATOR; Interventions: Other: EOX | Arm Label: mDCF; Type: ACTIVE_COMPARATOR; Interventions: Other: mDCF | Intervention Type: OTHER; Name: EOX; Assigned to Arm(s): EOX | Intervention Type: OTHER; Name: mDCF; Assigned to Arm(s): mDCF
D: Arm Label: CapeOx plus Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib, Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: CapeOx plus Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Capecitabine, Drug: Oxaliplatin | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): CapeOx plus Lapatinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CapeOx plus Placebo | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Brief Summary: This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.


Options:
A: Arm Label: C-CAR011; Type: EXPERIMENTAL; Interventions: Biological: C-CAR-011 | Intervention Type: BIOLOGICAL; Name: C-CAR-011; Assigned to Arm(s): C-CAR011
B: Arm Label: Tisagenlecleucel; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: Lymphodepleting chemotherapy | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: Lymphodepleting chemotherapy; Assigned to Arm(s): Tisagenlecleucel
C: Arm Label: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
D: Arm Label: Treatment (genetically modified T cell infusion); Type: EXPERIMENTAL; Interventions: Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, Procedure: autologous hematopoietic stem cell transplantation, Other: laboratory biomarker analysis | Intervention Type: BIOLOGICAL; Name: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; Assigned to Arm(s): Treatment (genetically modified T cell infusion) | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Treatment (genetically modified T cell infusion) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Treatment (genetically modified T cell infusion)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized Placebo Controlled Trial of Electroacupuncture for Women With Pure Stress Urinary Incontinence
Brief Summary: The purpose of this study is to preliminarily assess the efficacy of electroacupuncture (EA) for women with pure stress urinary incontinence (SUI).


Options:
A: Arm Label: Electrical pudendal nerve stimulation; Type: EXPERIMENTAL; Interventions: Behavioral: Electrical pudendal nerve stimulation | Arm Label: PFM training with Transvaginal ES; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PFM training, Behavioral: Transvaginal ES | Intervention Type: BEHAVIORAL; Name: Electrical pudendal nerve stimulation; Assigned to Arm(s): Electrical pudendal nerve stimulation | Intervention Type: BEHAVIORAL; Name: PFM training; Assigned to Arm(s): PFM training with Transvaginal ES | Intervention Type: BEHAVIORAL; Name: Transvaginal ES; Assigned to Arm(s): PFM training with Transvaginal ES
B: Arm Label: EA group; Type: ACTIVE_COMPARATOR; Interventions: Other: EA | Arm Label: Sham EA group; Type: PLACEBO_COMPARATOR; Interventions: Other: sham EA | Intervention Type: OTHER; Name: EA; Assigned to Arm(s): EA group | Intervention Type: OTHER; Name: sham EA; Assigned to Arm(s): Sham EA group
C: Arm Label: acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: acupuncture | Arm Label: Solifenacin plus PFMT; Type: ACTIVE_COMPARATOR; Interventions: Drug: solifenacin, Procedure: PFMT | Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): acupuncture | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin plus PFMT | Intervention Type: PROCEDURE; Name: PFMT; Assigned to Arm(s): Solifenacin plus PFMT
D: Arm Label: electroacupuncture group; Type: EXPERIMENTAL; Interventions: Device: electroacupuncture group | Arm Label: sham electroacupuncture group; Type: EXPERIMENTAL; Interventions: Device: sham electroacupuncture group | Intervention Type: DEVICE; Name: electroacupuncture group; Assigned to Arm(s): electroacupuncture group | Intervention Type: DEVICE; Name: sham electroacupuncture group; Assigned to Arm(s): sham electroacupuncture group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Design, Development And Validation Of A On-Line Intervention For Promoting Healthy Habits And Weight Loss In Hypertensive And Risk For Diabetes Mellitus People With Overweight And Type I Obesity
Brief Summary: Efficacy of an Internet-based self-guided intervention for promoting healthy habits and weight loss in hypertensive people with overweight and obesity: A Randomized Controlled Trial


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: Intensive therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle consultation: weight control, diet, exercise | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle consultation: weight control, diet, exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle consultation: weight control, diet, exercise; Assigned to Arm(s): Intensive therapy | Intervention Type: BEHAVIORAL; Name: Lifestyle consultation: weight control, diet, exercise; Assigned to Arm(s): Conventional therapy
C: Arm Label: Lifestyle on-line intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle on-line intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle on-line intervention; Assigned to Arm(s): Lifestyle on-line intervention
D: Intervention Type: BEHAVIORAL; Name: Weight reduction, Resistance training, Aerobic exercise training, Control; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stepped Wedge Trial of an Intervention to Support Proxy Decision Makers in ICUs
Brief Summary: This is a stepped wedged randomized controlled trial comparing the PARTNER intervention with usual care in 5 Intensive Care Units. The overarching goal of this research project to ensure patient-centered decisions about the use of intensive treatments for patients with advanced critical illness. In a prior project, the investigators developed the PARTNER program (PAiring Re-engineered ICU Teams with Nurse-driven Education and OutReach), a 4-facet, team-based intervention that re-engineers how surrogates are supported in ICUs, including: 1) changing care "defaults" to ensure clinician-family meetings within 48 hours of enrollment and frequently thereafter; 2) protocolized, nurse-administered coaching and emotional support of surrogates before and during clinician-family meetings, 3) increased use of palliative care services for patients with a poor prognosis. The investigators propose to begin deployment of the PARTNER II program in the spring of 2015 enrolling 690 surrogate decision makers in 5 ICUs using a stepped wedge design. The investigators expect to achieve the following project goals:

1. To increase the patient-centeredness of end-of-life decisions, and to increase the quality of clinician-family communication.
2. To decrease the psychological burden on family members acting as surrogates.
3. To reduce total health care costs by decreasing the duration of use of burdensome, invasive treatments at the end of life.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Decision support skills building Intervention | Intervention Type: BEHAVIORAL; Name: Decision support skills building Intervention; Assigned to Arm(s): 1
B: Arm Label: Feedback Group; Type: EXPERIMENTAL; Interventions: Behavioral: Communication Feedback Form for Patients with Serious Illness | Arm Label: Comparison/Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication Feedback Form for Patients with Serious Illness; Assigned to Arm(s): Feedback Group
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral: The PARTNER II Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PARTNER II | Intervention Type: BEHAVIORAL; Name: PARTNER II; Assigned to Arm(s): Behavioral: The PARTNER II Intervention
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: OTHER; Interventions: Other: Transition program | Intervention Type: OTHER; Name: Transition program; Assigned to Arm(s): Intervention Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cracking the Egg Potential: Improving Young Child Nutrition in Ecuador
Brief Summary: The proposed study will fill an important gap in the literature by examining, through a randomized controlled trial, the effect of egg consumption on biochemical markers of choline, vitamin B-12, lipids, and amino acids in young children in a poor rural area of Ecuador. Children from Cotopaxi Province, Ecuador (n=180) will be randomized into one of two groups: 1) intervention, receiving one egg per day for six months; or 2) control. Baseline and endline data on socio-economic factors, and child diet, morbidities, and anthropometry will be collected. Blood will also be drawn from the children at these time points for nutrient biomarker analyses. Through qualitative research the proposed study will provide insight into the attitudes, beliefs, and use of eggs by mothers and other caregivers during the complementary feeding period. The University of San Francisco in Quito (USFQ) will be the lead field coordinator of the research working in partnership with Washington University in St. Louis, Pan-American Health Organization (PAHO) and University of California, Davis.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Egg supplementation | Intervention Type: OTHER; Name: Egg supplementation; Assigned to Arm(s): Treatment
B: Arm Label: meat group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a high-protein complementary diet with meat | Arm Label: dairy group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a high-protein complementary diet with dairy | Intervention Type: BEHAVIORAL; Name: a high-protein complementary diet with meat; Assigned to Arm(s): meat group | Intervention Type: BEHAVIORAL; Name: a high-protein complementary diet with dairy; Assigned to Arm(s): dairy group
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2
D: Arm Label: Meat; Type: ACTIVE_COMPARATOR; Interventions: Other: Meat | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Arm Label: Fortified rice cereal; Type: ACTIVE_COMPARATOR; Interventions: Other: fortified rice cereal | Intervention Type: OTHER; Name: Meat; Assigned to Arm(s): Meat | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: fortified rice cereal; Assigned to Arm(s): Fortified rice cereal

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial to Investigate the Management for the Integral Assessment Model of Chronic Disease Supported in Information Technology and Communication.
Brief Summary: Controlled and Randomized Clinical trial with 3 parallel groups (intervention group with a health platform NOMHADchronic, phone-based care group, usual care group) developed in the Valencia La Fe Health Department. 495 high-complexity chronic patients will be included according to a combined recruitment based on a risk predictive model plus clinical opinion. Patients will be followed-up during 12 months in order to evaluate health-related quality of life, mortality, health consumption, health direct cost and treatment satisfaction.


Options:
A: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Support, management, educational, counselling, follow-up; Assigned to Arm(s): Group A, Group B
B: Arm Label: G_AH; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care group | Arm Label: G_SP; Type: OTHER; Interventions: Other: Phone-based care group | Arm Label: G_NOMHAD; Type: EXPERIMENTAL; Interventions: Device: Platform NOMHADchronic | Intervention Type: DEVICE; Name: Platform NOMHADchronic; Assigned to Arm(s): G_NOMHAD | Intervention Type: OTHER; Name: Phone-based care group; Assigned to Arm(s): G_SP | Intervention Type: OTHER; Name: Usual care group; Assigned to Arm(s): G_AH
C: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
D: Arm Label: Training; Type: EXPERIMENTAL; Interventions: Behavioral: Training | Arm Label: Usual care; Type: OTHER; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): Training | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care

Answer: B